WallStreetZenWallStreetZen

NASDAQ: AKBA
Akebia Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Akebia Therapeutics revenue was $160.18M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $46.5M, up 24.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AKBA annual revenue was $160.2M, with -17.7% growth year-over-year.

AKBA past revenue growth

How has AKBA's revenue growth performed historically?

Company
-17.7%
Industry
437.31%
Market
20.27%
AKBA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AKBA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AKBA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AKBA revenue history

Current Revenue
$160.2M
Current Earnings
-$69.4M
Current Profit Margin
-43.3%

Be the first to know when AKBA announces revenue.

AKBA Revenue History By Year

AKBA Yearly RevenueAKBA RevenueAKBA ChangeAKBA Revenue Growth
2024-12-31$160.18M-$34.44M-17.70%
2023-12-31$194.62M-$97.86M-33.46%
2022-12-31$292.48M$80.83M+38.19%
2021-12-31$211.65M-$82.99M-28.17%
2020-12-31$294.64M-$40.36M-12.05%
2019-12-31$335.00M$127.26M+61.26%
2018-12-31$207.74M$26.52M+14.63%
2017-12-31$181.23M$179.69M+11,706.32%
2016-12-31$1.54MN/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-28$0.00N/AN/A
2012-12-31$0.00N/AN/A

1 of 1

Akebia Therapeutics Revenue FAQ

What was AKBA's revenue last quarter?

On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q4 2024 revenue of $46.50 million up 17.26% year over year. In the same quarter last year, Akebia Therapeutics's revenue was $56.20 million.

What was Akebia Therapeutics's revenue in 2024?

Akebia Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $160.18 million, a 17.7% decrease year over year.

How much does Akebia Therapeutics make in a day?

Based on Akebia Therapeutics annual revenue for the past five years, AKBA makes an average of $632,099.18 per day.

What was Akebia Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Akebia Therapeutics's revenue has grown -17.7% year over year. This is 455.01 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Akebia Therapeutics's revenue in the past year totaled $160.18 million.

How much does Akebia Therapeutics make in a year?

Akebia Therapeutics's revenue by year for the past five years is:
  • Akebia Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $160.18 million, a 17.7% decrease year over year.
  • Akebia Therapeutics's annual revenue for Dec 31, 2023 was $194.62 million, a 33.46% decrease from 2022.
  • Akebia Therapeutics's annual revenue for 2022 was $292.48 million, a 38.19% increase from 2021.
  • Akebia Therapeutics's annual revenue for 2021 was $211.65 million, a 28.17% decrease from 2020.
  • Akebia Therapeutics's annual revenue for 2020 was $294.64 million, a 12.05% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.